linjc16/ctgov huggingface dataset:
Automated Dating Scan Probe Pressure Data Collection Plan

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to collect data in the form of ultrasound recordings from healthy volunteers, to aid the development of an Artificial Intelligence model that can identify ultrasound probe pressure.

Official Title
-----------------
A Volunteer Study to Collect Imaging Data for the Development of Identifying Probe Pressure as Part of ScanNav Assist Automated Dating Scan

Conditions
-----------------
Ultrasound

Intervention / Treatment
-----------------
* Other: Ultrasound Scans


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, at least 18 years of age; Able to comprehend and sign the Informed Consent prior to enrolment in the study. Exclusion Criteria: Aged <18 years of age; Unwilling or unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Volunteers<br>Healthy adult (18+ years old) volunteers | Other: Ultrasound Scans<br>* Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasound scan recordings | Ultrasound scan recordings collected by the volunteer healthy participants of an abdominal self-scan. | 6 months |
Tumors of the Peripheral Nervous System

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to individuate tumors' and patients' features influencing the outcome after surgical tumor removal.

Detailed Description
-----------------
Patients operated because of removal of Peripheral Nervous System (PNS) tumor will be recruited accordingly to the inclusion criteria: the aims of the study will be illustrated and the informed consent signed. All the clinical and neuroradiological perioperative documents of the enrolled patients will be analyzed. As follow-up, thorough neurological exam wil be performed and specific surveys about after surgery social and working life will be administered; neuroradiological imaging will be performed. Then, the results will be investigated to individuate which factors were related to the outcome.

Official Title
-----------------
Prognostic Factors in Tumors of the Peripheral Nervous System

Conditions
-----------------
Tumor of Peripheral Nerve

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 y.o. neurosurgical removal of peripheral nerve tumor at our University Hospital Fondazione Policlinico Universitario Agostino Gemelli (FPG) during the previous 10 years signed consent to study participation Exclusion Criteria: < 18 y.o. neurosurgical treatment because other causes (chronic entrapment syndromes, acute nerve lesion) denied consent to study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oncological outcome | number of patients with tumor relapses | through study completion, an average of 3 years | 
| functional outcome | evaluation of: 1) Motor function accordingly to the Medical Research Council muscle power scale (MRC); 2) Sensation accordingly to The Ten Test for Sensation (TTTS); 3) Pain accordingly to the Numerical Rating Scale for Pain (NRS). | through study completion, an average of 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
outcome, neurosurgery
A New Conception About Individualized Treatment Allocation for HCC

Study Overview
=================
Brief Summary
-----------------
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison of distinct therapies in similar populations. Here, the investigators aimed to develop and validate a new, integrated prognostic scheme for HCC patients using artificial intelligence (AI) to simulate the survival outcomes of patients allocated to different treatments.

Detailed Description
-----------------
Given that liver resection (LR) and transarterial chemoembolization (TACE) are the mainstay curative and palliative therapies for HCC, respectively, patients who underwent LR or TACE were included in the study. Various prognostic AI algorithms were modeled using data from a large multi-institutional cohort, where LR and TACE were considered independent factors. The C-index, Brier score (BS), and area under the receiver operating characteristic curve (auROC) were calculated to estimate the AI models.

Official Title
-----------------
A New Conception About Individualized Treatment Allocation for HCC-Using Machine Learning

Conditions
-----------------
HCC, Transarterial Chemoembolization, Resection

Intervention / Treatment
-----------------
* Procedure: TACE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Diagnosed with HCC Receiving LR or TACE therapy Complete clinical information Preserved liver function (Child-Pugh Score [CPS] ≤ 7) PS 0-1 Exclusion Criteria Vascular invasion or extrahepatic spread; Ecompensated liver cirrhosis ; Younger than 18 years; Duration of follow-up of fewer than 30 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TACE group<br>Incorporated HCC patients underwent TACE therapy. | Procedure: TACE<br> <br> |
| Liver resection group<br>Incorporated HCC patients underwent liver resection therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | Overall survival (OS) was defined as the time interval between initial TACE or LR and all-cause death. Patients who survived up to the last follow-up date | 5 years |
Efficacy of Acapella on Spirometry Measures in Patients With Bronchiectasis

Study Overview
=================
Brief Summary
-----------------
Acapella group. Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program . Only routine physical therapy program group ( control group). Will only take medications and routine chest physical therapy program.

Detailed Description
-----------------
Acapella group.Will use Acapella device for 3 times per day for 15 minutes for 7 days beside medications and routine chest physical therapy program. Only routine physical therapy program group( control group). Will only take medications and routine chest physical therapy program Spirometer measures such as forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) will be measured for every patient before and after the end of 7 days.

Official Title
-----------------
Efficacy of Acapella on Spirometry Measures in Patients With Bronchiectasis.

Conditions
-----------------
Bronchiectasis

Intervention / Treatment
-----------------
* Device: Acapella device
* Other: Only routine chest physical therapy program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bronchiectasis patients. Age range between 40 to 55 years old of both gender. Cooperative patients. Exclusion Criteria: Patients with severe cardiac disorders. Un controlled hypertensive patients. Un controlled diabetic patients.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Acapella<br>Will use Acapella device 3 times per day for 15 minutes for 7 days beside medications and routine physical therapy program. | Device: Acapella device<br>* Group A. Will use Acapella device.<br>Other: Only routine chest physical therapy program<br>* Group B. Will take medications and perform routine chest physical therapy program.<br>|
| Placebo Comparator: Only routine physical therapy program<br>Only they will receive medications and routine physical therapy program. | Other: Only routine chest physical therapy program<br>* Group B. Will take medications and perform routine chest physical therapy program.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spirometry measures | FVC, FEV1 | 7 days |
Impact of Black Seed Oil on Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the effect of black seed oil on endothelial dysfunction, oxidative stress and quality of life in hemodialysis patients.

Detailed Description
-----------------
Evaluation of the effect of black seed oil in hemodialysis patients via: Evaluation of serum Endothelin-1 levels Evaluation of serum Malondialdehyde (MDA) levels Evaluation of serum Total Antioxidant Capacity (TAC) levels Evaluation of Quality of Life (QOL) Evaluation of fatigue scale

Official Title
-----------------
Evaluation of the Impact of Black Seed Oil on Hemodialysis Patients

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Black Seed Oil
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 20 years old Three to four times per week hemodialysis Being on hemodialysis for at least 6 months Ability and willingness to cooperate in the study Exclusion Criteria: Pregnancy or lactation Cigarette smoking or substance/alcohol abuse Having active infectious diseases Receiving steroidal or nonsteroidal anti-inflammatory drugs Using Nigella sativa oil regularly Changes in treatment methods (dialysis) or medications during the supplementation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Drug vs placebo
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Black Seed Oil<br>900 mg (as two separate soft gels) twice daily for 8 weeks | Dietary Supplement: Black Seed Oil<br>* Dietary supplement<br>* Other names: Nigella sativa;|
| Placebo Comparator: Placebo<br>matched placebo capsules | Dietary Supplement: Placebo<br>* placebo capsules same odor, color and size as the drug but without the active ingredient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum Endothelin-1 (ET-1) level | marker of endothelial dysfunction | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum malondialdehyde (MDA) and total antioxidant capacity (TAC) | markers of oxidative stress | 8 weeks | 
| Quality of life questionnaire | using validated Arabic version SF-36 questionnaire | 4 weeks and 8 weeks | 
| Fatigue severity | using the Multidimensional Fatigue Inventory (MFI) | 4 weeks and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
black seed oil, nigella sativa, hemodialysis
Resistance Training in Children

Study Overview
=================
Brief Summary
-----------------
The project is going to examine the effects of resistance exercise training in prepubescent youth on skeletal muscle strength and lipid content.

Official Title
-----------------
The Effects of Resistance Training on Muscle Lipids in Children.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Resistance exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteer males and females ages 8 - 10 years. Exclusion Criteria: No history or ongoing neuromuscular diseases. No history or ongoing musculoskeletal injuries. No history or ongoing disease that effects metabolism.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Resistance exercise training<br>Participants undergo 24 sessions of resistance exercise training over about 8 weeks. | Other: Resistance exercise training<br>* Participants will strength train via linear periodization resistance exercise training.<br>|
| No Intervention: Control<br>Participants do not perform resistance exercise training. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the muscular strength of leg extensors, as measured with isotonic strength. | The score will reflect the strength of the leg extensors. The higher score, reflects greater muscular strength. | baseline, following the intervention (9 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in thigh muscle cross-sectional area. | Scores are measured cross-sectional area from ultrasound images. The higher score, reflects greater muscle size of the leg extensors. | baseline, following the intervention (9 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, muscle cross-sectional area, intramyocellular lipids, extramyocellular lipids, strength
The Neuroendocrine Effects of Pioglitazone in Patients With Lung Cancer and Cachexia

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is evaluate the effect of pioglitazone compared with placebo on skeletal muscle insulin sensitivity in subjects with advanced non-small-cell lung cancer and cachexia.

Official Title
-----------------
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Neuroendocrine Effects of Pioglitazone in Patients With Advanced Non-Small-Cell Lung Cancer and Cachexia

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Pioglitazone 45 mg
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Documented histologic or cytologic diagnosis of non-small-cell lung cancer that is locally advanced and inoperable or metastatic (e.g., spread to distant organs) Cachexia defined by Fearon criteria Insulin resistance syndrome, defined with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Ability to provide written informed consent, willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures Provide written approval by a qualified healthcare professional Allow the collection and storage of biospecimens and data for future use Exclusion Criteria: Prior diagnosis of type 2 diabetes Prior or current thiazolidinedione (TZD) therapy Known hypersensitivity to TZD New York Heart Association (NYHA) class I-IV heart failure History of or actively treated bladder cancer Current use of CYP2C inhibitor (e.g., gemfibrozil) or CYP2C inducer (e.g., rifampin) Inadequate hepatic function Currently pregnant, breastfeeding, or planning to become pregnant within the next 16 weeks Contraindications to magnetic resonance imaging (e.g., implanted cardiac device, cochlear implant) Any other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pioglitazone<br> | Drug: Pioglitazone 45 mg<br>* The dose of pioglitazone will not exceed 45 mg once daily. Pioglitazone dose will titrate progressively over the first three weeks.<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo will have the same appearance as the active drug.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in skeletal muscle insulin sensitivity | Quantified using hyperinsulinemic-euglycemic clamp | Baseline, Week 12 |
Hyperpolarized 129Xe MRI Lung Health Cohort

Study Overview
=================
Brief Summary
-----------------
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.

Official Title
-----------------
Hyperpolarized 129Xe MRI to Identify Structural Determinants of Low Lung Function and Respiratory Symptoms in Young Adults From the Lung Health Cohort

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Hyperpolarized Xe129


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is enrolled in the American Lung Association Lung Health Cohort Study. Has completed CT imaging for the LHC study within 2 years of the scheduled Xe-MRI date. Exclusion Criteria: Pacemaker, internal defibrillator or other implanted electronic devices or any standard MRI contraindications (e.g., claustrophobia, > 140 cm shoulder circumference, dependent on weight distribution). Is pregnant or breastfeeding Oxygen saturation (SpO2) <88% on room air or with supplemental oxygen.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal Lung Function<br>Participants with FEV1 > 85% predicted and no respiratory symptoms as determined at the baseline visit for the Lung Health Cohort | Drug: Hyperpolarized Xe129<br>* Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.<br>* Other names: Xenon, 129Xe, HP Xenon;|
| Low Normal Lung Function<br>Participants with FEV1 < 85% predicted as determined at the baseline visit for the Lung Health Cohort | Drug: Hyperpolarized Xe129<br>* Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.<br>* Other names: Xenon, 129Xe, HP Xenon;|
| Respiratory Symptoms<br>Participants with respirator symptoms as determined at the baseline visit for the Lung Health Cohort. | Drug: Hyperpolarized Xe129<br>* Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.<br>* Other names: Xenon, 129Xe, HP Xenon;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Xe-MRI Apparent Diffusion Coefficient | Correlation of Xe-MRI with FEV1/FVC and other measures of lung function | At baseline imaging timepoint |
Evaluation Of The Diagnostic Role Of Hysterosalpingography In Cesarean Scar Niche Diagnosed By Hysteroscopy

Study Overview
=================
Brief Summary
-----------------
The term CS niche (defect) describes the presence of a hypoechoic area within the myometrium in the isthmus (lower uterine segment) with discontinuation of myometrium at the site of previous CS. Hysterosalpingography is an important component in the diagnostic evaluation of the infertile woman. The number of hysterosalpingography examinations performed has significantly increased in recent years, likely due to the trend for women delaying pregnancy until later in life and the popularity of technical advances achieved in reproductive medicine.The term CS niche (defect) describes the presence of a hypoechoic area within the myometrium in the isthmus (lower uterine segment) with discontinuation of myometrium at the site of previous CS. The main purpose of the study is to evaluate the diagnostic role of HSG to early detect cesarean scar niche. To evaluate diagnostic role of hysterosalpingography (HSG) in cesarean scar niche at Early Cancer Detection and Gynecological Endoscopy Unit at Ain Shams Maternity Hospital within 6 months.

Official Title
-----------------
Evaluation Of The Diagnostic Role Of Hysterosalpingography In Cesarean Scar Niche Diagnosed By Hysteroscopy

Conditions
-----------------
Cesarean Section Complications

Intervention / Treatment
-----------------
* Radiation: hysterosalpingography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Age more than 18 years. Previous history of cesarean delivery. Cesarean scar niche confirmed by Hysteroscopy. Premenopausal status Exclusion Criteria: Pregnancy. Contrast allergy. Active pelvic infection. Medical history interfering with HSG.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cesarean section niche appearance | The ability of hysterosalpingography to detect the cesarean section niche appearance | baseline, pre-intervention |